Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Proactively manage your pharmacy inventory
Find generic entry opportunities
Anticipate generic drug launch
|Title:||Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic|
|Abstract:||The invention consists of a combination of a substance that increases the intragastric pH and an acid degradable antibacterial compound. By this combined product regimen it will be possible to obtain maximal local antibacterial effect of acid degradable antibiotics as well as enhanced bioavailability of the active antibiotic, thus resulting in higher amounts of the active compound in the gastric mucosa due to secretion of weak bases. Both pharmacological effects contribute to drastically increased antimicrobial capacity of acid degradable antibiotics to be used against local infections in the gastrointestinal tract causing gastritis and/or peptic ulcer. The invention also selects to the use of said combination and a process for the preparation thereof.|
|Inventor(s):||Eek; Arne T. (Trosa, SE), Sj ostrand; Sven Erik (S odert alje, SE)|
|Assignee:||Aktiebolaget Astra (Sodertalje, SE)|
Patent Claim Types:|
see list of patent claims
|Patent Number||Expiration Date|
|5,599,794||February 04, 2005|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||466||► subscribe|
|African Regional IP Organization (ARIPO)||9300518||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.